EVOK Evoke Pharma Inc.

2.36
+0.05  (2%)
Previous Close 2.31
Open 2.31
Price To book 18.15
Market Cap 36363789
Shares 15,413,610
Volume 5,768
Short Ratio 9.62
Av. Daily Volume 287,253

SEC filingsSee all SEC filings

  1. S-3/A [Amend] - Registration statement under Securities Act of 1933 171252546
  2. S-3 - Registration statement under Securities Act of 1933 171202305
  3. 8-K - Current report 171201967
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 171201677
  5. 8-K - Current report 171188393

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data released July 2016. Primary endpoint not met. However, the company noted December 15, 2016 that following discussions with FDA regarding possible NDA submission, no new efficacy or safety study would be required, if bioequivalence criteria were met in a pharmacokinetic (PK) trial. PK data released October 23, 2017, criteria met with NDA filing due 1Q 2018.
Gimoti - EVK-001
Female diabetic gastroparesis

SEC Filings

  1. S-3/A [Amend] - Registration statement under Securities Act of 1933 171252546
  2. S-3 - Registration statement under Securities Act of 1933 171202305
  3. 8-K - Current report 171201967
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 171201677
  5. 8-K - Current report 171188393
  6. 8-K - Current report 171148248
  7. CT ORDER - Confidential treatment order 171096655
  8. 8-K - Current report 171080109
  9. S-8 - Securities to be offered to employees in employee benefit plans 171030753
  10. 10-Q - Quarterly report [Sections 13 or 15(d)] 171030695